Related references
Note: Only part of the references are listed.Diagnosis and treatment of diffuse large B-cell lymphoma
Ulrich Mey et al.
SWISS MEDICAL WEEKLY (2012)
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Stephen M. Ansell et al.
LANCET ONCOLOGY (2011)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Sverker Hasselblom et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis
E. Suzuki et al.
ONCOGENE (2007)
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients
J. M. Li et al.
ANNALS OF HEMATOLOGY (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival
Shahab Uddin et al.
BLOOD (2006)
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab
Kathrin Wanner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas
GC Fillmore et al.
LEUKEMIA & LYMPHOMA (2005)
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern et al.
ANTI-CANCER DRUGS (2005)
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
DC Fingar et al.
ONCOGENE (2004)
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
JF Gera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang et al.
LEUKEMIA (2003)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
